Pierce Mattie Public Relations New York

Is it just me or was the last payment at the cosmetic surgeon’s office for your botox injection more painful than the needle itself? As the manufacturers of Reloxin went to the FDA this week to seek final US approval (but was delayed), one wonders just how much more affordable this Euro-type of botulinum toxin will be. Experts are projecting it to be about 15% less than Allergen's Botox Cosmetic. Most of us in Manhattan pay around $650.00 (give or take a few) for a full face. That would provide us with a savings of around $97.00 with estimates in time projected to be a 3rd of the market share. With the economy the way it is, I wonder if consumers will opt for the new Botox rival due to the affordability or simply remain loyal to Botox.

So what are your thoughts on this new injectable, will you be making your appointment this summer to flatten your furrows? Let me know your thoughts.